All the pyrrolobenzodiazepines tested - SJG136, SGD-1882, SG2057, and SG3199 - were substrates of P-gp, ABCG2, and MRP1. The modified anthracyclines nemorubicin and its metabolite PNU-159682 were poorly transported by both ABCB1 and ABCG2 and displayed nanomolar to picomolar toxicity. Further, we found that the efficacy of the FDA-approved ADC mirvetuximab soravtansine, with DM4 as the toxic payload, was decreased in cell lines expressing P-gp... Several commonly used ADC payloads can be transported by ABC transporters, potentially leading to transporter-mediated drug resistance in patients. Future ADCs should be developed using payloads that are not ABC transporter substrates.

P1/2, N=55, Not yet recruiting, SN BioScience

P1, N=21, Completed, SN BioScience | Not yet recruiting --> Completed | N=36 --> 21 | Trial completion date: Jun 2025 --> Jan 2026 | Trial primary completion date: Dec 2024 --> Jan 2026

Rutin mitigates THP-induced cardiotoxicity and enhances chemotherapeutic efficacy via the novel miR-129-1-3p/GRIN2D pathway. Our data show miR-129-1-3p to be an essential mediator, and suggest that the rutin-miR-129-1-3p-GRIN2D axis is a favorable target for improving the safety and effectiveness of breast cancer chemotherapy.

The impact of HER2 expression on the recurrence-free survival (RFS) of patients with intravesical anthracycline (epirubicin or pirarubicin) instillation after transurethral resection of bladder tumor (TURBT) was evaluated. In the patients treated with intravesical anthracycline instillation, HER2 high-expression was associated with a shorter RFS (P<0.001). HER2 high-expression seems to be not only associated with worse clinicopathological features of NMIBC but also a poor RFS in NMIBC patients treated with anthracycline instillation after TURBT.

In addition, compared with the control group, the tumor volume in the THP@TEVs group was reduced by approximately 62.1% (p<0.001, n=5) and no histopathological changes were observed in major organs (such as heart, liver, spleen, lungs, and kidneys) upon H&E staining. This study provides a precise, low-toxicity chemotherapy and immune synergistic strategy for TNBC and expands the potential of TEVs in tumor therapy.

P1/2, N=22, Completed, Moleculin Biotech, Inc. | Active, not recruiting --> Completed | N=63 --> 22

P1, N=20, Recruiting, Valent Technologies, LLC | Trial completion date: Jun 2025 --> Jun 2026 | Trial primary completion date: Jun 2025 --> Jun 2026

The patient underwent 4 courses of chemotherapy with ifosfamide and pirarubicin. The findings from this case highlight the morphologic and immunohistochemical features that are diagnostic of this rare uterine tumor. Furthermore, this report summarizes the morphologic criteria for malignancy and the key points for its differential diagnosis.

Additionally, 7MW4911 showed favorable pharmacokinetics and a highest non-severely toxic dose (HNSTD) exceeding 20 mg/kg in cynomolgus monkeys, underscoring its promising safety profile. Together, these findings position 7MW4911 as a promising ADC candidate capable of enhancing therapeutic outcomes in GI cancers.

All the pyrrolobenzodiazepines tested - SJG136, SGD-1882, SG2057, and SG3199 - were substrates of P-gp, ABCG2, and MRP1. The modified anthracyclines nemorubicin and its metabolite PNU-159682 were poorly transported by both ABCB1 and ABCG2 and displayed nanomolar to picomolar toxicity. Further, we found that the efficacy of the recently FDA-approved ADC mirvetuximab soravtansine, which has DM4 as the toxic payload, was decreased in cell lines with overexpression of P-gp. Several commonly used ADC payloads can be effluxed from cells by ABC transporters which may lead to transporter-mediated drug resistance in patients. Future ADCs should be developed using payloads that are not substrates of ABC transporters.

P1, N=9, Completed, Engeneic Pty Limited | Unknown status --> Completed | N=20 --> 9